KNSA

Kiniksa Pharmaceuticals International, plc

Nasdaq · Pharmaceutical Preparations · CIK 0001730430
$51.89 +0.60% $4.0B
Insider Selling Cluster (3 insiders)High Impact Filing (8/10)
Vol
Market Cap$4.0B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (93%)
Insider Activity0B / 10S
Insider Net $-$11.2M
SEC Reports9
Exchange Nasdaq·Sector Pharmaceutical Preparations·CIK 0001730430·Prev Close $51.58

Recent Activity

Jun 1, 2026 Insider
Patel Sanj K acquired 900,000 shares
CHAIRMAN & CEO
Jun 1, 2026 Insider
Patel Sanj K disposed of 900,000 shares
CHAIRMAN & CEO
May 29, 2026 other
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
<p>LONDON, May 29, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PF
May 29, 2026 Insider
Levy Richard S was granted 2,026 shares
Director
May 26, 2026 SEC
Kiniksa entered into a deed of waiver with Baker Bros. Advisors LP, under which Baker Bros. irrevocably waived its conve
8-K — Impact 3/10
May 5, 2026 SEC
Kiniksa Pharmaceuticals insiders, including CEO and CMO, sold $5.28M in shares during the week following strong Q1 2026
CLUSTER — Impact 4/10
May 1, 2026 SEC
Chief Strategy Officer Eben Tessari resigned effective May 15, 2026 to pursue another executive position in life science
8-K — Impact 2/10

Price Targets

$63.50 +22.4% upside Strong Buy
Current $51.89 Low $57.00 Median $62.00 High $72.00 8 analysts
$57.00 $72.00

Analyst Ratings

Strong Buy93% buy · 14 analysts
5Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
Apr 29, 2026 Canaccord Genuity MAINTAIN Buy → Buy
Apr 29, 2026 Citigroup MAINTAIN Buy → Buy
Apr 29, 2026 Wedbush MAINTAIN Outperform → Outperform
Apr 29, 2026 Wells Fargo MAINTAIN Overweight → Overweight
Apr 28, 2026 Jefferies MAINTAIN Buy → Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $0.29 ▲ +10.9% $0.27 — $0.31 28% YoY 4
Next Q $0.32 ▲ +5.4% $0.29 — $0.36 40% YoY 4
Current FY $1.20 $1.10 — $1.35 60% YoY 4
Next FY $1.76 ▲ +8.4% $1.32 — $2.03 46% YoY 4

Latest Reports

NEUTRAL 8-K 3/10
Kiniksa entered into a deed of waiver with Baker Bros. Advisors LP, under which Baker Bros. irrevocably waived its conve
May 26, 2026
NEUTRAL CLUSTER 4/10
Kiniksa Pharmaceuticals insiders, including CEO and CMO, sold $5.28M in shares during the week following strong Q1 2026
May 5, 2026

Recent Insider Trades

DateInsiderTypeValue
Jun 1, 2026Patel SanjC$0.00
Jun 1, 2026Patel SanjC$0.00
May 29, 2026Levy RichardA$0.00
May 29, 2026McCain TraceyM$0.00
May 29, 2026Malley ThomasA$0.00
∅

No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.

12 unique insiders with 50 transactions. Net insider value: -$11.2M ($0.00 bought, $11.2M sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
Jun 1, 2026Patel Sanj KCHAIRMAN & CEOCONVERT900,000——
Jun 1, 2026Patel Sanj KCHAIRMAN & CEOCONVERT900,000——
May 29, 2026Levy Richard SDirectorAWARD2,026——
May 29, 2026McCain Tracey LDirectorEXERCISE2,799——
May 29, 2026Malley ThomasDirectorAWARD12,158——
May 29, 2026McCain Tracey LDirectorAWARD12,158——
May 29, 2026Malley ThomasDirectorAWARD2,026——
May 29, 2026Malley ThomasDirectorEXERCISE2,799——
May 29, 2026Levy Richard SDirectorAWARD12,158——
May 29, 2026Cole G BradleyDirectorEXERCISE2,799——
May 29, 2026McCain Tracey LDirectorAWARD2,026——
May 29, 2026Cole G BradleyDirectorAWARD12,158——
May 29, 2026Cole G BradleyDirectorAWARD2,026——
May 29, 2026Levy Richard SDirectorEXERCISE2,799——
May 29, 2026Popovits Kimberly JDirectorAWARD12,158——
May 29, 2026Popovits Kimberly JDirectorAWARD2,026——
May 29, 2026Popovits Kimberly JDirectorEXERCISE2,799——
May 29, 2026Quart Barry DDirectorEXERCISE2,799——
May 29, 2026Quart Barry DDirectorAWARD12,158——
May 29, 2026Quart Barry DDirectorAWARD2,026——
May 1, 2026Patel Sanj KCHAIRMAN & CEOSELL48,565$54.02$2.6M
May 1, 2026Patel Sanj KCHAIRMAN & CEOEXERCISE48,565$30.93$1.5M
May 1, 2026Paolini John F.CHIEF MEDICAL OFFICEREXERCISE58,424$10.36$605.3K
May 1, 2026Paolini John F.CHIEF MEDICAL OFFICERSELL37,327$53.52$2.0M
Apr 30, 2026Patel Sanj KCHAIRMAN & CEOSELL2,141$54.01$115.6K
Apr 30, 2026Patel Sanj KCHAIRMAN & CEOEXERCISE2,141$30.93$66.2K
Apr 29, 2026Patel Sanj KCHAIRMAN & CEOEXERCISE22,544$30.93$697.3K
Apr 29, 2026Patel Sanj KCHAIRMAN & CEOSELL22,544$54.01$1.2M
Apr 28, 2026Quart Barry DDirectorEXERCISE13,099$14.33$187.7K
Apr 28, 2026Quart Barry DDirectorSELL13,099$50.10$656.3K
Apr 28, 2026Patel Sanj KCHAIRMAN & CEOEXERCISE431,904$10.36$4.5M
Apr 28, 2026Patel Sanj KCHAIRMAN & CEOSELL74,635$50.43$3.8M
Apr 9, 2026Megna Michael RCHIEF ACCOUNTING OFFICERSELL6,625$46.69$309.3K
Apr 9, 2026Moat RossCHIEF OPERATING OFFICERSELL1,703$46.69$79.5K
Apr 7, 2026Megna Michael RCHIEF ACCOUNTING OFFICEREXERCISE3,932$1.00$3.9K
Apr 7, 2026Megna Michael RCHIEF ACCOUNTING OFFICERTAX W/H1,666$48.94$81.5K
Apr 7, 2026Moat RossCHIEF OPERATING OFFICERTAX W/H774$48.94$37.9K
Apr 7, 2026Paolini John F.CHIEF MEDICAL OFFICERTAX W/H1,208$48.94$59.1K
Apr 7, 2026Moat RossCHIEF OPERATING OFFICEREXERCISE2,477——
Apr 7, 2026Paolini John F.CHIEF MEDICAL OFFICEREXERCISE2,497——
Apr 7, 2026Ragosa MarkCHIEF FINANCIAL OFFICEREXERCISE2,694——
Apr 7, 2026Ragosa MarkCHIEF FINANCIAL OFFICERTAX W/H1,303$48.94$63.8K
Apr 7, 2026Patel Sanj KCHAIRMAN & CEOEXERCISE9,991——
Apr 7, 2026Patel Sanj KCHAIRMAN & CEOTAX W/H4,831$48.94$236.4K
Apr 7, 2026Tessari EbenCHIEF STRATEGY OFFICEREXERCISE2,726——
Apr 7, 2026Tessari EbenCHIEF STRATEGY OFFICERTAX W/H846$48.94$41.4K
Apr 6, 2026Quart Barry DDirectorSELL6,901$50.00$345.1K
Apr 6, 2026Quart Barry DDirectorEXERCISE6,901$14.33$98.9K
Apr 6, 2026Moat RossCHIEF OPERATING OFFICERSELL2,367$48.58$115.0K
Apr 6, 2026Patel Sanj KCHAIRMAN & CEOEXERCISE7,278$10.36$75.4K
9 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 1 mixed, 5 neutral. Avg impact: 4.4/10.
NEUTRAL 8-K 3/10
Kiniksa entered into a deed of waiver with Baker Bros. Advisors LP, under which Baker Bros. irrevoca
May 26, 2026
NEUTRAL CLUSTER 4/10
Kiniksa Pharmaceuticals insiders, including CEO and CMO, sold $5.28M in shares during the week follo
May 5, 2026
NEUTRAL 8-K 2/10
Chief Strategy Officer Eben Tessari resigned effective May 15, 2026 to pursue another executive posi
May 1, 2026
NEUTRAL CLUSTER 3/10
Kiniksa Pharmaceuticals CEO Sanj K. Patel and Director Barry D. Quart sold a combined $4.42M in open
Apr 30, 2026
BEARISH 144 6/10
Sanj K. Patel, CEO of Kiniksa Pharmaceuticals, filed a Form 144 to sell 344,591 Class A Ordinary Sha
Apr 28, 2026
BULLISH PRESS-RELEASE 8/10
Kiniksa reported Q1 2026 revenue of $214.3M (56% YoY growth) and GAAP diluted EPS of $0.27, beating
Apr 28, 2026
NEUTRAL PRESS-RELEASE 3/10
Kiniksa Pharmaceuticals announced it will report its Q1 2026 financial results on April 28, 2026, vi
Apr 23, 2026
BEARISH CLUSTER 6/10
Three corporate insiders at Kiniksa Pharmaceuticals sold shares in open-market transactions totaling
Apr 13, 2026
MIXED CLUSTER 5/10
Kiniksa Pharmaceuticals insiders executed a cluster of transactions over a 7-day window, including o
Apr 8, 2026
∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Current analyst consensus: Strong Buy (93% buy). Based on 14 analysts: 5 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$63.50 mean target +22.4% upside Strong Buy (1.13)
$57.00 Low $72.00 High
MetricValue
Current Price$51.89
Target Low$57.00
Target Mean$63.50
Target Median$62.00
Target High$72.00
# Analysts8
RecommendationStrong Buy (1.13)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $0.29 $0.27 $0.31 28.3% +10.9% 1↑ 1↓ $0.2B 44.5% 4
Next Q
2026-09-30
 $0.32 $0.29 $0.36 40.2% +5.4% 1↑ 1↓ $0.2B 33.4% 4
Current FY
2026-12-31
 $1.20 $1.10 $1.35 60.0% +0.0% 1↑ 1↓ $0.9B 38.7% 4
Next FY
2027-12-31
 $1.76 $1.32 $2.03 46.5% +8.4% 3↑ 1↓ $1.1B 19.9% 4

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$0.295
7d ago$0.217+0.078
30d ago$0.266+0.029
60d ago$0.285+0.010
90d ago$0.380-0.085
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Apr 29, 2026 Canaccord Genuity MAINTAIN Buy Buy
Apr 29, 2026 Citigroup MAINTAIN Buy Buy
Apr 29, 2026 Wedbush MAINTAIN Outperform Outperform
Apr 29, 2026 Wells Fargo MAINTAIN Overweight Overweight
Apr 28, 2026 Jefferies MAINTAIN Buy Buy
Apr 16, 2026 Wedbush MAINTAIN Outperform Outperform
Feb 25, 2026 Wells Fargo MAINTAIN Overweight Overweight
Feb 25, 2026 Wedbush MAINTAIN Outperform Outperform
Feb 19, 2026 Canaccord Genuity INITIATE — Buy
Jan 13, 2026 Wedbush MAINTAIN Outperform Outperform

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20265810093%
May 1, 20265810093%
Apr 1, 20265810093%
Mar 1, 20265810093%
Feb 1, 20265710092%
Jan 1, 20265710092%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 29, 2026
other
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
<p>LONDON, May 29, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PFddqFj96cwGm0rcpJr1XkYC9yiZU2sXkki04sxtQNi1exnJZ2X3
Apr 28, 2026
earnings
Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution
<p align="center"><em>– ARCALYST</em><sup><em>®</em></sup><em> (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-
Apr 28, 2026
earnings_calendar
KNSA Q1 2026 Earnings Scheduled — 2026-04-28
Apr 23, 2026
earnings
Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026
<p>LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=3OkEUzLXuFKh086440LkeY_llVsfP71x_Z6Dj2-PNPiM3M2Pya
Apr 21, 2026
earnings_calendar
KNSA Q1 2026 Earnings Scheduled — 2026-04-21
Apr 20, 2026
short_volume
Short Volume: KNSA — 58.4% short (0.3M / 0.5M)
Short: 310,843 | Exempt: 0 | TRF Vol: 532,335 | Short Ratio: 58.4% | Off-exchange volume (dark pool + OTC)
Mar 27, 2026
short_volume
Short Volume: KNSA — 84.4% short (0.5M / 0.6M)
Short: 508,698 | Exempt: 0 | TRF Vol: 602,870 | Short Ratio: 84.4% | Off-exchange volume (dark pool + OTC)